Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when QDEL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Revenue Guidance Narrowed to Low End With Conditional Assumptions (new) — Management's full-year outlook explicitly excludes prolonged China reimbursement pressure or extended Middle East conflict, creating downside risk if either condition persists.
- Multiple Simultaneous Headwinds (new) — The Q1 miss stems from three concurrent issues (weak respiratory season, China slowdown, EMEA delays), raising questions about whether management can offset all three in remaining quarters.
QuidelOrtho pre-announces Q1 revenue miss at $615-620M, cuts full-year outlook to low end
Filed April 15, 2026 · Period ending April 15, 2026 · ~1 min read
Key Changes
-
high
Q1 2026 revenue of $615-620M falls short of prior guidance, driven by 30% drop in U.S. flu visits, China distributor slowdown tied to proposed reimbursement cuts, and Middle East conflict delays in EMEA.
Exhibit 99.1 view on EDGAR → -
high
Management narrows full-year 2026 guidance to the low end of prior range, warning that outlook assumes no prolonged China reimbursement headwinds or extended Middle East disruptions.
Exhibit 99.1 view on EDGAR → -
medium
Q1 free cash flow expected at negative $65-70M, consistent with prior first-half burn guidance; full-year 2026 free cash flow still expected positive.
Exhibit 99.1 view on EDGAR → -
medium
CEO emphasizes core business (over 70% of revenue) remains strong, suggesting revenue miss concentrated in respiratory and China-exposed segments rather than broad-based weakness.
Exhibit 99.1 view on EDGAR →
Summary
QuidelOrtho pre-announced a material Q1 2026 revenue shortfall, guiding to $615-620 million versus prior expectations, and effectively lowered full-year guidance by stating only the low end of its February range remains achievable.
The miss was driven by a weaker-than-expected U.S. respiratory season (flu visits down 30% year-over-year), slower China distributor sales tied to proposed government reimbursement cuts, and delayed EMEA orders due to Middle East conflict disruptions.
Management reaffirmed positive full-year free cash flow despite a $65-70 million Q1 cash burn, and emphasized that the core business (over 70% of revenue) remains strong, suggesting the weakness is concentrated in respiratory and China-exposed segments. Retail investors should note two concerns. First, the updated full-year guidance explicitly assumes no prolonged impact from China reimbursement changes or Middle East disruptions—if either persists, further downside is likely. Second, the company faces three simultaneous headwinds (respiratory seasonality, China policy risk, geopolitical disruption), and the ability to offset all three in the remaining three quarters is uncertain. The pre-announcement ahead of the May 5 earnings call signals management wanted to reset expectations early, but the conditional nature of the guidance and the breadth of the challenges warrant close monitoring of Q2 execution and any updates on China reimbursement policy.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
This preliminary unaudited revenue was primarily driven by a weaker respiratory season, with U.S. Influenza-like Illness visits down by approximately 30% compared to the first quarter of 20251, along with slower China distributor sales that the Company believes is related to the proposed China National Health Security Administration (“NHSA”) reimbursement rate reductions. Additionally, certain EMEA orders were delayed by the Middle East conflict, negatively impacting first quarter revenue.
The revenue shortfall was driven by three factors: U.S. flu visits down approximately 30% year-over-year (a weaker respiratory season), slower China distributor sales linked to proposed NHSA reimbursement rate cuts, and delayed EMEA orders due to Middle East conflict disruptions. These headwinds hit the company's respiratory and international businesses simultaneously.
Added in current filing · view on EDGAR →
Based on current information, the Company believes the low end of its full-year 2026 financial guidance (issued February 11, 2026) remains achievable. The ranges provided by the Company were intentionally broad to reflect variability in the respiratory season and other factors, and do not assume a significant, prolonged impact from China NHSA reimbursement initiatives or continued disruption related to the Middle East conflict.
Management stated that the low end of full-year 2026 guidance (originally issued February 11, 2026) remains achievable, effectively narrowing the range and lowering expectations. The guidance does not assume prolonged China NHSA reimbursement headwinds or extended Middle East conflict disruptions, suggesting further downside risk if those conditions persist.
Event · Item 2.02 — Results of Operations and Financial Condition
QuidelOrtho disclosed preliminary unaudited Q1 2026 revenue results via press release.
Added in current filing · verify on EDGAR →
On April 15, 2026, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing its preliminary unaudited revenue for its first quarter of 2026, ended March 29, 2026.
QuidelOrtho announced preliminary unaudited revenue for the first quarter ended March 29, 2026. The 8-K does not disclose the actual revenue figures in the body text; those details are contained in the press release furnished as Exhibit 99.1. This is a routine quarterly revenue pre-announcement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 26, 2026 · How we verify